Clinical trial
A Phase I, Non-randomized, Open-label, Single-dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of MDV3100 in Male Subjects With Mild or Moderate Hepatic Impairment and Normal Hepatic Function
NCT01901133 is registered in ClinicalTrials.gov with Astellas Pharma Europe B.V. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Non-randomized, Open-label, Single-dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of MDV3100 in Male Subjects With Mild or Moderate Hepatic Impairment and Normal Hepatic Function
- Lead sponsor
- Astellas Pharma Europe B.V.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 31, 2011
- Completion date
- January 31, 2012
- Enrollment
- 33 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
healthy subjects, kidney diseases, pharmacokinetics of mdv3100